Ascentage Pharma Group Appoints Two Independent Non-Executive Directors

Ascentage Pharma Group International is pleased to announce the appointment of Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors of the Company, effective November 25, 2024. Both appointments are subject to re-election by shareholders at the Company’s upcoming Annual General Meeting (AGM). They will hold office until the first general meeting following their appointments.

Ms. Marina Bozilenko, aged 59, currently serves as the President, CEO, and Director at Biothea Pharma, Inc., and as an Independent Director at Talphera, Inc. She has held leadership positions at various prestigious companies, including William Blair & Co. LLC, Bear, Stearns & Co., Inc., and Banc of America Securities LLC. Ms. Bozilenko has extensive experience in the healthcare and finance sectors, having also served as a Director at Olema Pharmaceuticals, Inc. and SynAct Pharma AB.

She holds a bachelor's degree in biochemistry and a master’s degree in social sciences from The University of Chicago. Ms. Bozilenko’s appointment is a result of a recommendation by the Company’s Nomination Committee and approval by the Board. Her term of service will be three years, with a director’s fee of USD 60,000 per annum.

Dr. Debra Yu, aged 60, is the Chief Operating Officer and Partner at Panacea Venture. She also serves as a board member at MeiraGTx Holdings PLC and as an Independent Non-Executive Director at JW (Cayman) Therapeutics Co. Ltd. Dr. Yu’s career includes roles at LianBio, China Renaissance Securities (U.S.), and WuXi AppTec, Inc. She holds a medical degree from Harvard Medical School and a bachelor’s degree in molecular biology from Princeton University. Dr. Yu’s appointment also follows the recommendation of the Nomination Committee and approval by the Board. She will serve a three-year term, with a director’s fee of USD 60,000 per annum.

Both Ms. Bozilenko and Dr. Yu have confirmed their independence and have no financial or other connections to the Group that might affect their impartiality. The Board warmly welcomes them to the Company, confident that their expertise and experience will contribute to Ascentage Pharma's continued growth and success. The appointments are part of Ascentage Pharma’s commitment to strengthening corporate governance and supporting the ongoing expansion of the business.